Compass Therapeutics, Inc. (CMPX): Cash & Equivalents
$30.64M
As of 2025-12-31
$35.45M
As of 2026-06-30
-4.3%
3-year compound annual growth
-8.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $30.64M | -29.5% | 2026-03-05, Balance as of period end |
| 2024-12-31 | $43.48M | +79.5% | 2026-03-05, Balance as of period end |
| 2023-12-31 | $24.23M | -30.7% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $34.95M | -75.8% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $144.51M | +207.0% | 2023-03-15, Balance as of period end |
| 2020-12-31 | $47.08M | n/a | 2022-03-18, Balance as of period end |
| 2020-03-31 | $3.7K | n/a | 2020-06-08, Balance as of period end |
| 2019-12-31 | $25.30M | n/a | 2021-03-05, Balance as of period end |
| 2019-03-31 | $4.9K | n/a | 2020-06-08, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $30.64M | -29.5% |
| Amgen Inc (AMGN) | 2025-12-31 | $9.13B | -23.8% |
| Repligen Corp (RGEN) | 2025-12-31 | $566.02M | -25.3% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $264.71M | +63.2% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | $89.74M | -14.3% |
| Vericel Corp (VCEL) | 2025-12-31 | $100.09M | +34.3% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $713.00M | +206.0% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $482.49M | +122.0% |
Compare CMPX, AMGN, RGEN, TECH side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗